Welcome to Dr. Elliott Antman's AHA Emerging Science™ Series.

AHA is proud to introduce a new program to further science collaboration hosted by Dr. Elliot Antman: The AHA Emerging Science™ Series webinars are one hour professional quality webinars held three times per year. Dr. Antman will host each webinar, which will have two 30 minute blocks, consisting of presentations of original research from the following categories:

  • Late Breaking Clinical Trials
  • Clinical Trial Updates of previously presented LBCTs
  • Late Breaking Basic Science
  • Major Bench-to-Bedside Advances
  • Major Conference Proceedings
  • Major Guidelines/Policy Statements

The live webinar events will be viewable from a computer or mobile phone, both live and on-demand. Attendees can ask questions electronically during the live event or post event. 

Join us at the next event, or view for past events by visiting the Emerging Science Series page on Professional Heart Daily.

Latest Posts

The American Heart Association presents breaking Science News from the Emerging Science Series webinar, held April 24, 2013.  View the archived webinar, in addition to presentation slides, summary slides, and abstracts in Circulation.

  • Preclinical data supporting off-the-shelf bioengineered vascular grafts in hemodialysis
  • Challenges, opportunities and next steps in CVD cell-based therapies

Robert O. Bonow, MD, FAHA
Northwestern University Feinberg School of Medicine
Past AHA President and Chair of the Emerging Science Series Committee


Timothy J. Gardner, MD
Christian Care Health System
Newark, DE

Alan Nugent, MD, MBBS
UT Southwestern Medical Center
Dallas, TX

Asian Teyfik Turer, MD, MHS
UT Southwestern Medical Center
Dallas, TX


Human Acellular Vascular Grafts: Preclinical Dataset Supports Bench-to-Bedside Transition of Tissue-Engineered Grafts for Hemodialysis Vascular Access
Presenter: Shannon L.M. Dahl, PhD,Humacyte, Inc., Durham, NC

Bringing Tissue Engineered Technologies to Clinical and Commercial Relevance in Cardiovascular Medicine
Presenter: Todd McAllister, PhD, Cytograft Tissue Engineering, Novato, CA


Posted by Alyson PON Editor on Apr 29, 2013 9:24 AM CDT

Protecting Cerebrovascular Function - From Translational Science to Clinical Trials

Wednesday, April 25, 2012, Noon–1:05 p.m.

Presentation Topics: 
  1. Outcomes of Discontinuing Rivaroxaban Compared with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Analysis from the ROCKET AF Trial  
    Presenter: Jonathan P. Piccini, Duke Clinical Res Inst, Duke Univ Medical Ctr, Durham, NC
    View abstract   |   Science News Summary 
  2. Cerebrovascular Autoregulation Impairment is Associated with Elevations in Plasma Glial Fibrillary Acidic Protein During Congenital Heart Surgery  
    Presenter: Ronald B. Easley, Baylor Coll of Med, Houston, TX
    View manuscript   |   Science News Summary
Posted by Alyson PON Editor on Apr 24, 2012 9:32 AM CDT
First Human Use of an Allogeneic Tissue Engineered Vascular Graft
Description: A first-in-human study to test the feasibility of an allogeneic tissue-engineered vascular graft
Presenter: Todd N. McAllister, Novato, Calif.

  • Timothy J Gardner
  • Elliott Antman
  • Robert Harrington
  • Donna Arnett
  • Eric R Bates
  • Conville BrownFrank Sellke
Posted by Alyson PON Editor on Mar 9, 2012 12:42 PM CST
The Emerging Science™ Series presents chosen science submissions in a free webinar

Date: June 27, 2011
Time: 12-1:05 p.m. Central Time(USA) :UTC/GMT -5

Presentation Topics:
1. First Human Use of an Allogeneic Tissue Engineered Vascular Graft
Description: A first-in-human study to test the feasibility of an allogeneic tissue-engineered vascular graft. 
Presenter: Todd N. McAllister, Novato, Calif.
2. Ticagrelor Compared with Clopidogrel by Geographic Region in the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Description: Presentation of the regional variation in outcomes in PLATO with an emphasis on the North American cohort.
Presenter: Kenneth W. Mahaffey, Durham, N.C.

Moderators: Timothy J. Gardner, Elliott Antman, and Robert Harrington

Panelists: Donna Arnett, Eric R. Bates, Conville Brown, and Frank Sellke

Posted by Elliott Antman on Jun 7, 2011 11:21 AM CDT
In this video, Dr. Harrington talks about how the Emerging Science™ Series offers exciting benefits for researchers. more...
Posted by Elliott Antman on Apr 22, 2011 6:24 PM CDT
Welcome to the AHA Emerging Science™ Series and Scientific Sessions blog!  View the video below to find out more about this exciting new program.

Posted by Elliott Antman on Apr 19, 2011 3:56 PM CDT

Introduction to the ESS:
Beginning in 2011, AHA is giving you an opportunity to present your best science through the new Emerging Science™ Series.  The new, online event will feature a free webinar presentation of cutting-edge science. This live, moderated event and online forum will have submission opportunities for late-breaking clinical trials, key updates of previously presented trials, late-breaking basic science,major Bench-to-Bedside Breakthroughs, major conference proceedings, and major Guidelines/Policy Statements.Ample time will be allocated for a discussion forum and questions submitted from the audience. 
Posted by Elliott Antman on Apr 18, 2011 5:53 PM CDT

Most Recent Comments

I am intrigued by this exciting new AHA Emerging Science Series, and particularly interested to hear the discussion on the US subgroup analysis from PLATO.
I am very enthusiastic to hear more about tissue engineered vascular grafts. The science is quite provocative and the potential for clinical application is substantial!
As the Director of the Adult Invasive and Interventional Cardiology Program in Nassau, The Bahamas, I am excited to join the panel to discuss the implications of the PLATO US subgroup findings. Clearly dual antiplatelet therapy is at the center of the pharmacologic support for PCI and we need to understand the optimal regimen to protect our patients.
I am pleased to see a translational science presentation in this first webinar of the AHA Emerging Science Series. Using allogeneic fibroblasts to build a tissue engineered vascular graft is a creative approach to a common clinical problem. I look forward to learning more about how this was done and the results in the first in human experience.
The PLATO US substudy raises a number of important questions that will attract the attention of clinical trialists, interventional cardiologists, and vascular biologists. Should be an interesting discussion.